Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
BACKGROUND: Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. METHODS: DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences...
February 28, 2024: Prostate Cancer and Prostatic Diseases